Strides Arcolab shares sink on dividend worries

MUMBAI Thu Feb 28, 2013 9:51am IST

Related Topics

Stocks

   

MUMBAI (Reuters) - Shares in drugmaker Strides Arcolab (STAR.NS) plummeted about 10 percent on Thursday, wiping out early gains following its sale of a unit to Mylan (MYL.O) for $1.6 billion, as investors were unhappy with Strides' dividend payout, traders said.

The shares had initially gained as much as 13.2 percent.

The company declared a 20 percent dividend, or 2 rupees per share, for 2012.

Strides' injectables unit Agila Specialties generated $700 million in sales and an operating profit of $86 million in year 2012, Strides said.

The Bangalore-based drugmaker said it planned to spend $700 million to $800 million at pretax level on shareholders.

Valued at $1.1 billion, shares in Strides Arcolab were down 8.5 percent at 902.95 rupees by 9:51 a.m. when the Mumbai market was up 0.55 percent.

(Reporting by Kaustubh Kulkarni; Editing by Gopakumar Warrier)

FILED UNDER:

Economic Pulse

REUTERS SHOWCASE

Gold Imports

Gold Imports

India eases gold import rule in surprise move.  Article 

Indians in Iraq

Indians in Iraq

India says no contact with 39 men held by Islamic State in Iraq.  Full Article 

Sahara Issue

Sahara Issue

Sahara looks to raise $650 million loan to fund bail.  Full Article 

Bhopal Tragedy

Bhopal Tragedy

Bhopal's toxic legacy lives on, 30 years after industrial disaster.  Full Article 

Banking Sector

Banking Sector

After record deal, more India bank takeovers on cards  Full Article 

Islamic Fund

Islamic Fund

India gets new Islamic equity fund but debt market still off-limits  Full Article 

Cricket Tragedy

Cricket Tragedy

Clarke breaks down giving heartfelt Hughes tribute  Full Article 

Nigeria Violence

Nigeria Violence

Bombs, gunfire kill 81 at crowded mosque in Nigeria's Kano  Full Article 

Movie Review

Movie Review

D’Silva's “Ungli” just skims the surface  Full Article | Related Story 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage